95 related articles for article (PubMed ID: 6383687)
1. Neomycin and plasma lipoproteins in type II hyperlipoproteinemia.
Hoeg JM; Schaefer EJ; Romano CA; Bou E; Pikus AM; Zech LA; Bailey KR; Gregg RE; Wilson PW; Sprecher DL
Clin Pharmacol Ther; 1984 Oct; 36(4):555-65. PubMed ID: 6383687
[TBL] [Abstract][Full Text] [Related]
2. Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin.
Hoeg JM; Maher MB; Bou E; Zech LA; Bailey KR; Gregg RE; Sprecher DL; Susser JK; Pikus AM; Brewer HB
Circulation; 1984 Dec; 70(6):1004-11. PubMed ID: 6388897
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
Hoeg JM; Maher MB; Zech LA; Bailey KR; Gregg RE; Lackner KJ; Fojo SS; Anchors MA; Bojanovski M; Sprecher DL
Am J Cardiol; 1986 Apr; 57(11):933-9. PubMed ID: 3515897
[TBL] [Abstract][Full Text] [Related]
4. Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
Hoeg JM; Maher MB; Bailey KR; Zech LA; Gregg RE; Sprecher DL; Brewer HB
Am J Cardiol; 1985 May; 55(11):1282-6. PubMed ID: 3887883
[TBL] [Abstract][Full Text] [Related]
5. The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia.
Hoeg JM; Maher MB; Bailey KR; Brewer HB
Atherosclerosis; 1986 Jun; 60(3):209-14. PubMed ID: 3524586
[TBL] [Abstract][Full Text] [Related]
6. Controlled trial of acifran in type II hyperlipoproteinemia.
Hunninghake DB; Edwards KD; Sopko GS; Tosiello RL
Clin Pharmacol Ther; 1985 Sep; 38(3):313-7. PubMed ID: 4028627
[TBL] [Abstract][Full Text] [Related]
7. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment.
Gurakar A; Hoeg JM; Kostner G; Papadopoulos NM; Brewer HB
Atherosclerosis; 1985 Nov; 57(2-3):293-301. PubMed ID: 2935163
[TBL] [Abstract][Full Text] [Related]
8. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
9. The effects of thiazide diuretics upon plasma lipoproteins.
Johnson BF; Saunders R; Hickler R; Marwaha R; Johnson J
J Hypertens; 1986 Apr; 4(2):235-9. PubMed ID: 3519766
[TBL] [Abstract][Full Text] [Related]
10. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
11. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Grundy SM; Knopp RH; Lasser NL; Mellies MJ; Palmer RH; Samuel P
Arteriosclerosis; 1986; 6(6):670-8. PubMed ID: 3535757
[TBL] [Abstract][Full Text] [Related]
12. Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients.
LaRosa JC; Miller VT; Edwards KD; DeBovis MR; Stoy DB
Artery; 1987; 14(6):338-50. PubMed ID: 3314798
[TBL] [Abstract][Full Text] [Related]
13. Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin.
Farnsworth WH; Hoeg JM; Maher M; Brittain EH; Sherins RJ; Brewer HB
J Clin Endocrinol Metab; 1987 Sep; 65(3):546-50. PubMed ID: 3114306
[TBL] [Abstract][Full Text] [Related]
14. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
15. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
16. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
Series JJ; Gaw A; Kilday C; Bedford DK; Lorimer AR; Packard CJ; Shepherd J
Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
[TBL] [Abstract][Full Text] [Related]
17. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia.
Mol MJ; Erkelens DW; Leuven JA; Schouten JA; Stalenhoef AF
Lancet; 1986 Oct; 2(8513):936-9. PubMed ID: 2877129
[TBL] [Abstract][Full Text] [Related]
18. The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia.
Ayres EJ; Hoeg JM; Bailey KR; Bieri JG
Drug Nutr Interact; 1986; 4(4):325-31. PubMed ID: 3792214
[TBL] [Abstract][Full Text] [Related]
19. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
Uglesić A; Ljachnicky N
Schweiz Rundsch Med Prax; 1988 Jul; 77(27-28):755-61. PubMed ID: 3041534
[No Abstract] [Full Text] [Related]
20. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
